WO2023044700A1 - Method and aqueous gel for treating oral mucositis - Google Patents

Method and aqueous gel for treating oral mucositis Download PDF

Info

Publication number
WO2023044700A1
WO2023044700A1 PCT/CN2021/120097 CN2021120097W WO2023044700A1 WO 2023044700 A1 WO2023044700 A1 WO 2023044700A1 CN 2021120097 W CN2021120097 W CN 2021120097W WO 2023044700 A1 WO2023044700 A1 WO 2023044700A1
Authority
WO
WIPO (PCT)
Prior art keywords
water
organic silver
silver ion
ion compound
oral mucositis
Prior art date
Application number
PCT/CN2021/120097
Other languages
French (fr)
Chinese (zh)
Inventor
王式禹
Original Assignee
世福莱德生技股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 世福莱德生技股份有限公司 filed Critical 世福莱德生技股份有限公司
Priority to PCT/CN2021/120097 priority Critical patent/WO2023044700A1/en
Publication of WO2023044700A1 publication Critical patent/WO2023044700A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/28Compounds containing heavy metals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02Local antiseptics

Definitions

  • the present invention relates to a method for treating oral mucositis, which includes providing a water-based gel containing a water-soluble organic silver ion compound, and applying it to damaged oral mucosa with an appropriate application method, and is mainly used in the treatment of oral mucosa Inflammation (Oral Mucositis).
  • the method of the present invention is mainly applied to patients with oral mucositis caused by cancer radiotherapy and chemotherapy, but it can also be applied to patients with oral mucosa inflammation or ulcers caused by other factors.
  • the present invention is also related to a treatment for oral mucositis
  • the water-based gel is characterized in that the composition of the water-based gel contains a water-soluble organic silver ion compound and a polymer thickener.
  • the water-based gel When used, the water-based gel will be used due to the viscosity and shear thinning characteristics of the water-based gel.
  • the damaged oral mucosa can stay for a long time, so that the water-soluble organic silver ion compound in the water-based gel can fully exert its effect, and promote the recovery of the damaged oral mucosa during radiotherapy and chemotherapy.
  • Oral mucositis is one of the lesions that occur in the oral mucosa. Oral mucositis especially refers to the oral mucosal lesions, ulcers and inflammation caused by the treatment of cancer patients during chemotherapy and radiation therapy. It is a kind of It is a very common complication after chemical drug treatment and radiation therapy. Severe oral mucositis can cause cancer patients to have difficulty eating and swallowing. In severe cases, they will die due to inability to eat and cause insufficient nutrition to fight cancer.
  • hematopoietic stem cell transplantation hematopoietic stem cell transplantation
  • the main treatment method is usually local medication in the oral cavity, including the application of local analgesics, such as the use of narcotic preparations (Lidocaine, Benzocaine or benzydamine) Sprays, gels or mouthwashes, use topical anti-inflammatory agents such as steroid preparations (apply Nincort intraoral gel, Salcoat oral spray capsules), use topical antiseptics such as mouthwashes containing chlorohexidine.
  • local analgesics such as the use of narcotic preparations (Lidocaine, Benzocaine or benzydamine) Sprays, gels or mouthwashes
  • topical anti-inflammatory agents such as steroid preparations (apply Nincort intraoral gel, Salcoat oral spray capsules)
  • use topical antiseptics such as mouthwashes containing chlorohexidine.
  • a water-based gel used to reduce the discomfort or pain of oral mucositis such as Gelclair, which is a thick liquid that is used like a mouthwash and can be used directly or diluted Use, the main function is to form a protective layer on the damaged oral mucosa to reduce the discomfort and pain of patients with oral mucositis, but this type of aqueous gel can only relieve the discomfort of oral mucositis, and cannot improve the oral mucosa Symptoms of inflammation.
  • the inventors of the present invention have found that water-soluble organic silver ion compounds are very effective for treating oral mucositis, and have developed a method of using water-soluble organic silver ion compounds to treat oral mucositis and water-based solutions containing water-soluble organic silver ion compounds. gel.
  • the present invention mainly relates to a method for treating oral mucositis, which includes providing a water-based gel containing a water-soluble organic silver ion compound, and applying it to the damaged oral mucosa with an appropriate application method, mainly for the treatment of radiotherapy and chemotherapy
  • the cancer patients treated of course, in addition to the oral mucositis patients generally obtained during the chemotherapy and radiation therapy of cancer, there are also patients with recurrent aphthous ulcer (Recurrent aphthous Ulcer) and those caused by wearing braces.
  • Oral ulcer patients or patients with oral ulcers caused by other diseases can use the method of the present invention.
  • Oral mucositis is one of the common side effects after receiving chemotherapy and radiotherapy, and it often occurs in 4-7 days and 7-14 days after chemotherapy and reaches the peak.
  • the stomatitis caused by radiation therapy may start around 2-3 weeks and reach its peak in the late stage of treatment.
  • Symptoms of oral mucositis include dry mouth, bad breath, inflammation and pain, etc. In severe cases, mucosal damage or ulcers in the oral cavity or oropharynx, bleeding, changes in taste, difficulty in swallowing and speaking, etc. may occur.
  • the World Health Organization grading standard for oral mucositis divides the condition of the oral mucosa into 5 grades, grade 0 is no change in the oral mucosa, grade 1 is oral mucosa pain and erythema, and grade 2 is oral mucosa pain and erythema combined Ulcers, can eat solid food, grade 3 is oral mucosa pain and erythema combined with ulcers, can only eat liquid food, grade 4 is oral mucosa pain and erythema combined with ulcers, unable to eat.
  • the methods of the present invention may be used with damaged oral mucosa at any of the grades described above.
  • the water-based gel in the present invention is a viscous water-based gel containing a water-soluble organic silver ion compound. Its use method is very diverse. It can be similar to mouthwash, and an appropriate amount of the water-based gel of the present invention can be poured into the mouth. In the mouth, use the oral movement to evenly distribute the water-based gel to the damaged mucosa of the mouth, then hold the water-based gel in the mouth for a period of time, and then spit it out. Or it can be sprayed on the damaged oral mucosa in the mouth, or it can be sprayed deeper into the throat. It can also be smeared on damaged oral mucosa.
  • this aqueous gel Due to the viscous and shear-thinning characteristics of this aqueous gel, it can stay on the damaged oral mucosa for a long time, so that the water-soluble organic silver ion compound in the aqueous gel can play its role more effectively .
  • the aqueous gel of the present invention contains a water-soluble organic silver ion compound and also contains a polymer thickener, and its effect is to improve the viscosity of the aqueous gel of the present invention.
  • a suitable polymer thickener includes Cellulose, Acrylic (polyacrylate), natural gum, polyvinylpyrrolidone (polyvinylpyrrolidone) and other water-based organic thickeners, cellulose thickeners include sodium carboxylmethyl cellulose, methyl cellulose ( Methyl Cellulose), Hydroxypropylmethylcellulose, Hydroxypropylcellulose, Hydroxyethyl cellulose, Microcrystalline cellulose or other water-soluble thickeners Efficient cellulose derivatives, acrylics include polyacrylic acid, sodium polyacrylate, copolymers of acrylic acid and other acrylic monomers, copolymers of sodium acrylate and other acrylic monomers, or other water-soluble thickeners Water-soluble acrylic polymer with agent performance, natural gum contains guar gum (Guar gum),
  • the above polymer thickener will also give the water-based gel of the present invention the characteristics of shear thinning (Shear thinning), which makes the water-based gel of the present invention During use, it can stay in the oral mucosa for a long time, so that the water-soluble organic silver ion compound in the water-based gel can play its role more effectively.
  • Shear thinning shear thinning
  • the property of shear thinning is a characteristic of a non-Newtonian fluid, that is, the viscosity of the fluid decreases with the increase of the shear force, which is different from the viscosity of the Newtonian body that does not change with the change of the shear force.
  • the specific advantage of the property of shear thinning in the use of the hydrogel of the present invention is to make the application method more acceptable to the user, and to allow the water-soluble organic silver polymer to contact the damaged oral mucosa for a longer period of time. to fully utilize its effectiveness,
  • the water-based gel When the water-based gel is used in the form of mouthwash, when it is poured into the mouth, the movement of the oral cavity exerts a shear force on the water-based gel. The faster the frequency of oral movement, the greater the shear force, because The water-based gel of the present invention has the property of shear thinning, so its viscosity will be much lower. A low-viscosity mouthwash will be more acceptable to users than a high-viscosity mouthwash, and it will also make the water-based gel easier to process. And more completely cover every mucous membrane in the oral cavity, whether it is damaged or undamaged mucous membranes can be covered.
  • the shear force is zero, and the water-based gel of the present invention has increased viscosity and is not easy to flow when remaining on the oral mucosa, so it can stay on the damaged mucosa, and because of its high viscosity, it is not easy to be washed away by saliva in the oral cavity, making the water-based gel It can stay on the damaged mucosa for a long time, and the water-soluble organic silver ion compound in the water-based gel can also play its role more effectively.
  • the same water-based gel of the present invention When used in the form of a spray, the same water-based gel of the present invention is subjected to the power given by the spray bottle when spraying out, and is sprayed at a high speed. At this time, the water-based gel is thinned by shearing characteristics and the viscosity is reduced, so that the water-based gel can be sprayed out smoothly. When it is sprayed on the damaged oral mucosa, the force of the nozzle has disappeared and the viscosity of the water-based gel has increased, so it can stay on the damaged oral mucosa for a long time. On the mucous membrane, the water-soluble organic silver ion compound in the aqueous gel can also play its role more effectively.
  • the same water-based gel of the present invention When used in the way of smearing, the same water-based gel of the present invention is subjected to the force applied when smearing and the viscosity is reduced, so that the water-based gel can be smoothly applied to the damaged oral mucosa.
  • the viscosity of the water-based gel of the present invention increases because the force of smearing has disappeared, so it can stay on the damaged mucosa for a long time, and the water-soluble organic silver ion compound in the water-based gel also to play its role more effectively.
  • the nature of shear thinning is usually represented by Thixotropic Index, which refers to the viscosity ratio measured under low and high shear forces. If the Thixotropic Index is equal to 1, it represents the The fluid is a Newtonian fluid, and if the thixotropy index is greater than 1, it means that the fluid is non-Newtonian and has the property of shear thinning.
  • the rotation of the fluid is used to measure the viscosity of the fluid, and the magnitude of the shear force is represented by the rotational speed of the cone and the spindle.
  • the thixotropic index defined in the present invention refers to the viscosity ratio measured when the rotating speed of the cone or spindle is 1 revolution per second and 10 revolutions per second.
  • the thixotropy index of the aqueous gel of the present invention must be greater than 1.1, more preferably greater than 1.5, and more preferably greater than 2.
  • the effective substance contained in the aqueous gel for treating oral mucositis is a water-soluble organic silver ion compound
  • the water-soluble organic silver ion compound can be a small molecule organic silver ion compound or a macromolecular organic silver ion compound .
  • the small-molecule organic silver ion compound of the present invention refers to organic silver salts with a molecular weight less than 1000, including but not limited to organic silver salts of carboxylates, organic silver sulfonates, and complexes of organic heterocyclic compounds and silver ions.
  • the solubility of the ionic compound in water at normal temperature (25°C) must be greater than 0.01%, preferably greater than 0.1%, more preferably greater than 1%.
  • the organic silver carboxylate salt of the present invention can be the alkyl organic carboxylate silver salt that generally contains 1 to 10 carbon number, such as silver formate, silver acetate, silver propionate, silver butyrate etc., or it may contain other water-soluble functional groups
  • Alkyl organic carboxylic acid silver salts such as the organic carboxylic acid silver salts with the chemical formula CH 3 -O-(CH 2 CH 2 O) n -CH-COOAg mentioned in European Patent EP2159270A1, or other structures silver salts of organic carboxylic acids.
  • the organic sulfonate silver salt of the present invention can be silver toluenesulfonate or other organic sulfonate silver salts.
  • the complex compound of organic heterocyclic compound and silver ion of the present invention can be the complex compound of imidazole compound (imidazole compound) or triazole compound (triazole compound) and silver, for example in document (Dalton Trans.,2009,6985-6990 ) The water-soluble imidazole/silver complexes and water-soluble triazole/silver complexes studied in ), or the complexes of other heterocyclic compounds and silver.
  • the macromolecular organic silver ion compound of the present invention can be the water-soluble acrylic polymer silver salt disclosed in US Pat.
  • the silver content in the aqueous gel of the present invention must be at least greater than 10ppm, preferably greater than 50ppm, and more preferably greater than 150ppm. The higher the silver ion content, the better the effect of treating oral mucositis.
  • the aqueous gel of the present invention can also add appropriate flavoring agents to increase user acceptance, such as sweeteners or cooling agents.
  • the raw material of the aqueous gel contains polyvinylpyrrolidone (Polyvinylpyrrolidone, BASF) and hydroxypropylmethylcellulose (Hydroxypropylmethylcellulose, Metolose 90SH-100000SR, Shin-Etsu), the water-soluble organic silver ion compound used is macromolecular sodium acrylate-silver acrylate copolymer (Poly(sodium acrylate-co -silver acrylate), provided by Cunshengtai International Co., Ltd., which provides sodium acrylate-silver acrylate copolymer solution (Poly(sodium acrylate-co-silver acrylate) solution), sodium acrylate-silver acrylate copolymer solution
  • the sodium acrylate-silver acrylate copolymer content is 2.5%, and the silver ion content is 1%, that is, each sodium acrylate-silver acrylate copolymer molecule contains an average
  • composition of the aqueous gel is shown in the table below, as shown in the table, the silver content in the prepared aqueous gel is 150ppm (0.015%), and the viscosity measured at 1 revolution per second with the Brookfield DV1 rheometer is 367cps, and the viscosity at 10 revolutions per second is 298cps, the thixotropic index of this aqueous gel is 1.23.
  • CCRT concurrent chemoradiotherapy
  • the intervention of hydrogel was given on the 23rd day (T0) after the start of the treatment, and he was asked to take it after meals every day.
  • gargling before going to bed gargle for at least one minute each time, spit out the water-based gel after rinsing, and have a weekly oral examination by an oral surgeon according to the Oral Assessment Guildline (OAG, Oral Assessment Guildline).
  • CCRT concurrent chemoradiotherapy
  • the intervention of hydrogel was given on the 16th day (T0) after the start of the treatment, and he was asked to eat after meals and Rinse your mouth before going to bed, gargle for at least one minute each time, spit out the water-based gel after rinsing, and have a weekly oral examination by an oral surgeon according to the Oral Assessment Guildline (OAG, Oral Assessment Guildline). 4 weeks (T1 to T4) until the end of the course of treatment, the results are shown in the table below:
  • the intervention of hydrogel was given on the 27th day (T0) after the start of treatment. She was asked to rinse her mouth after meals and before going to bed every day. Gargle for at least one minute at a time, and spit out the water-based gel after rinsing.
  • the oral cavity is checked by an oral surgeon according to the Oral Assessment Guildline (OAG, Oral Assessment Guildline) every week for a total of 4 weeks (T1 to T4) So until the end of its course of treatment, the results are shown in the table below:

Abstract

Disclosed is an aqueous gel for treating oral mucositis, which is characterized in that same contains a water-soluble organic silver ion compound and a polymer thickener. The aqueous gel is used in the preparation of a drug for treating oral mucositis, in particular oral mucositis caused by cancer chemoradiotherapy. When in use, due to the viscosity and the shear thinning characteristic of the aqueous gel, the aqueous gel can stay on the damaged oral mucosa for a long time, so that the effectiveness of the water-soluble organic silver ion compound in the aqueous gel can be fully realized, and the restoration of damaged oral mucosa in the chemoradiotherapy process is promoted.

Description

治疗口腔黏膜炎的方法与水性凝胶Method and aqueous gel for treating oral mucositis 技术领域technical field
本发明是有关一种治疗口腔黏膜炎的方法,此方法包含提供一含有水溶性有机银离子化合物的水性凝胶,以及以适当的施用方法施用于受损的口腔黏膜,主要应用在治疗口腔黏膜炎(Oral Mucositis)。本发明的方法主要应用在因癌症放化疗而引起的口腔黏膜炎患者上,但是也可应用在其他因素造成的口腔黏膜发炎或溃疡的患者上,本发明同时也是有关于一种治疗口腔黏膜炎的水性凝胶,其特色在于此水性凝胶的成分中含有水溶性有机银离子化合物与高分子增稠剂,使用时会因为水性凝胶的黏稠性与剪切稀化特性使得水性凝胶在受损的口腔黏膜上得以停留较长的时间,因而让水性凝胶中的水溶性有机银离子化合物得以充分发挥其效用,促进因放化疗治疗过程中受损的口腔黏膜的复原。The present invention relates to a method for treating oral mucositis, which includes providing a water-based gel containing a water-soluble organic silver ion compound, and applying it to damaged oral mucosa with an appropriate application method, and is mainly used in the treatment of oral mucosa Inflammation (Oral Mucositis). The method of the present invention is mainly applied to patients with oral mucositis caused by cancer radiotherapy and chemotherapy, but it can also be applied to patients with oral mucosa inflammation or ulcers caused by other factors. The present invention is also related to a treatment for oral mucositis The water-based gel is characterized in that the composition of the water-based gel contains a water-soluble organic silver ion compound and a polymer thickener. When used, the water-based gel will be used due to the viscosity and shear thinning characteristics of the water-based gel. The damaged oral mucosa can stay for a long time, so that the water-soluble organic silver ion compound in the water-based gel can fully exert its effect, and promote the recovery of the damaged oral mucosa during radiotherapy and chemotherapy.
背景技术Background technique
口腔黏膜炎(Oral Mucositis)是发生在口腔黏膜的病变之一,口腔黏膜炎特别指癌症病患在化学药物治疗和放射线治疗期间因治疗所引起的口腔黏膜病变、溃疡及发炎反应,是一种很常见的化学药物治疗和放射线治疗后引起的并发症,严重的口腔黏膜炎会导致癌症患者进食困难与吞咽不易,更严重者会因无法进食导致营养不足无法对抗癌症而死亡。Oral mucositis (Oral Mucositis) is one of the lesions that occur in the oral mucosa. Oral mucositis especially refers to the oral mucosal lesions, ulcers and inflammation caused by the treatment of cancer patients during chemotherapy and radiation therapy. It is a kind of It is a very common complication after chemical drug treatment and radiation therapy. Severe oral mucositis can cause cancer patients to have difficulty eating and swallowing. In severe cases, they will die due to inability to eat and cause insufficient nutrition to fight cancer.
接受高剂量化学疗法与造血干细胞移植疗法((hemato poietic stem cell transplantation)的癌症病患有几乎100%的机率会得到口腔黏膜炎,80%接受放射治疗的头颈部恶性肿瘤患者会得到口腔黏膜炎,而在接受化学治疗的癌症患者中有高达40-70%的比例会得到不同程度的口腔黏膜炎。Cancer patients receiving high-dose chemotherapy and hematopoietic stem cell transplantation (hemato poietic stem cell transplantation) have almost 100% chance of getting oral mucositis, and 80% of patients with head and neck malignancies receiving radiation therapy will get oral mucositis Oral mucositis occurs in up to 40-70% of cancer patients receiving chemotherapy.
当口腔黏膜炎发生时除了必须加强口腔的清洁及护理以外,通常以口腔内的局部用药为主要的治疗方法,包含了施用局部止痛剂,例如使用含麻醉药制 剂(Lidocaine、Benzocaine或benzydamine)的喷剂、凝胶或漱口水,使用局部抗发炎剂,例如类固醇药制剂(涂抹Nincort宁康口内胶、Salcoat口腔喷雾胶囊),使用局部抗菌剂,例如含有chlorohexidine的漱口水。When oral mucositis occurs, in addition to the need to strengthen the cleaning and care of the oral cavity, the main treatment method is usually local medication in the oral cavity, including the application of local analgesics, such as the use of narcotic preparations (Lidocaine, Benzocaine or benzydamine) Sprays, gels or mouthwashes, use topical anti-inflammatory agents such as steroid preparations (apply Nincort intraoral gel, Salcoat oral spray capsules), use topical antiseptics such as mouthwashes containing chlorohexidine.
以上的局部治疗效果并不十分显著,研究显示含有chlorohexidine抗菌剂的漱口水对于口腔黏膜炎没有太大的效果(European Journal of Cancer Care,2006,15,431–439),当口腔黏膜炎程度严重时,局部涂抹药物变得非常麻烦,以致治疗效果会因而降低。The above local treatment effects are not very significant. Studies have shown that mouthwash containing chlorohexidine antibacterial agent has no great effect on oral mucositis (European Journal of Cancer Care, 2006, 15, 431–439). When oral mucositis is severe, Topical application of the drug becomes very cumbersome, so that the therapeutic effect will be reduced.
另外有一种用来降低口腔黏膜炎不舒适或疼痛的水性凝胶,例如商品名为Gelclair的水性凝胶,是一种浓稠的液体,其使用方法类似漱口水,可以直接使用,也可稀释使用,主要功能是在受损的口腔黏膜上形成一层保护层以降低口腔黏膜炎患者的不舒适与疼痛感,但是这类水性凝胶仅仅可以减缓口腔黏膜炎的不适,并无法改善口腔黏膜炎的症状。There is also a water-based gel used to reduce the discomfort or pain of oral mucositis, such as Gelclair, which is a thick liquid that is used like a mouthwash and can be used directly or diluted Use, the main function is to form a protective layer on the damaged oral mucosa to reduce the discomfort and pain of patients with oral mucositis, but this type of aqueous gel can only relieve the discomfort of oral mucositis, and cannot improve the oral mucosa Symptoms of inflammation.
本发明的发明者发现水溶性的有机银离子化合物对于治疗口腔黏膜炎非常有效,因而开发了一种使用水溶性有机银离子化合物以治疗口腔黏膜炎的方法以及含有水溶性有机银离子化合物的水性凝胶。The inventors of the present invention have found that water-soluble organic silver ion compounds are very effective for treating oral mucositis, and have developed a method of using water-soluble organic silver ion compounds to treat oral mucositis and water-based solutions containing water-soluble organic silver ion compounds. gel.
发明内容Contents of the invention
本发明主要关于一种治疗口腔黏膜炎的方法,此方法包含提供一含有水溶性有机银离子化合物的水性凝胶,以及以适当的施用方法施用于受损的口腔黏膜,主要是针对接受放化疗治疗的癌症病患,当然除了一般在癌症的化学药物治疗和放射线治疗期间因治疗而得到的口腔黏膜炎患者外,还有复发性阿弗他溃疡(Recurrent aphthous Ulcer)患者、因戴牙套而引起的口腔溃疡患者或因其他疾病(如糖尿病、手口足病)而引起的口腔溃疡患者都可以使用本发明的方法。The present invention mainly relates to a method for treating oral mucositis, which includes providing a water-based gel containing a water-soluble organic silver ion compound, and applying it to the damaged oral mucosa with an appropriate application method, mainly for the treatment of radiotherapy and chemotherapy The cancer patients treated, of course, in addition to the oral mucositis patients generally obtained during the chemotherapy and radiation therapy of cancer, there are also patients with recurrent aphthous ulcer (Recurrent aphthous Ulcer) and those caused by wearing braces. Oral ulcer patients or patients with oral ulcers caused by other diseases (such as diabetes, hand-mouth-foot disease) can use the method of the present invention.
口腔黏膜炎是接受化学治疗及放射治疗后常见的副作用之一,常出现于化 学治疗后4-7天、7-14天达到高峰期。而放射治疗造成的口腔炎,可能在第2-3周左右开始,于治疗晚期达最高峰。口腔黏膜炎症状有口干、口臭、发炎疼痛等,严重会出现口腔或口咽部位黏膜破损或溃疡、出血、味觉改变、吞咽及说话困难等情形。Oral mucositis is one of the common side effects after receiving chemotherapy and radiotherapy, and it often occurs in 4-7 days and 7-14 days after chemotherapy and reaches the peak. The stomatitis caused by radiation therapy may start around 2-3 weeks and reach its peak in the late stage of treatment. Symptoms of oral mucositis include dry mouth, bad breath, inflammation and pain, etc. In severe cases, mucosal damage or ulcers in the oral cavity or oropharynx, bleeding, changes in taste, difficulty in swallowing and speaking, etc. may occur.
一般受损的口腔黏膜评估主要有三种评量标准可供选择,分别是世界卫生组织口腔黏膜炎分级标准(World Health Organization Oral Toxicity scale),口腔评估指南(OAG,Oral Assesment Guildline)以及美国国家癌症研究所的常见不良反应事件评价标准(National Cancer Institute Common Toxicity Criteria for Adverse Events,NCI-CTCAE V5.0,2017),这些评量标准将口腔黏膜的受损程度分级以方便对癌症病人进行口腔黏膜受损程度的分析以及照护。Generally, there are three evaluation standards to choose from for the evaluation of damaged oral mucosa, which are the World Health Organization Oral Toxicity scale, the Oral Assessment Guildline (OAG, Oral Assessment Guildline) and the National Cancer Institute of the United States. The Institute's Common Toxicity Criteria for Adverse Events (National Cancer Institute Common Toxicity Criteria for Adverse Events, NCI-CTCAE V5.0, 2017), these evaluation standards grade the degree of damage to the oral mucosa to facilitate the evaluation of oral mucosa in cancer patients Damage analysis and care.
例如世界卫生组织口腔黏膜炎分级标准将口腔黏膜的状况分为5个等级,第0级是口腔黏膜无变化,第1级是口腔黏膜疼痛及红斑,第2级是口腔黏膜疼痛及红斑而且合并溃疡,可进食固体食物,第3级是口腔黏膜疼痛及红斑而且合并溃疡,仅可进食流质食物,第4级是口腔黏膜疼痛及红斑而且合并溃疡,无法进食。For example, the World Health Organization grading standard for oral mucositis divides the condition of the oral mucosa into 5 grades, grade 0 is no change in the oral mucosa, grade 1 is oral mucosa pain and erythema, and grade 2 is oral mucosa pain and erythema combined Ulcers, can eat solid food, grade 3 is oral mucosa pain and erythema combined with ulcers, can only eat liquid food, grade 4 is oral mucosa pain and erythema combined with ulcers, unable to eat.
本发明的方法可以使用在以上所述任何等级状况的受损的口腔黏膜。The methods of the present invention may be used with damaged oral mucosa at any of the grades described above.
本发明中的水性凝胶一种含有水溶性有机银离子化合物的黏稠性水性凝胶,其使用方式非常多样化,可以类似漱口液的方式,将适量本发明的水性凝胶倒入口中,含于口中,借助口腔运动将水性凝胶均匀的分布覆盖至口腔的受损黏膜上,之后将水性凝胶含在口腔中一段时间,然后吐掉即可。或者可以喷剂的形式,喷于口腔中受损的口腔黏膜上,也可更深层的喷至咽喉部。也可以涂抹的方式,涂于受损的口腔黏膜上。由于此水性凝胶具有黏稠与胶剪切稀化的特性,因此可以在受损伤的口腔黏膜上停留较长的时间,让水性凝胶中的水 溶性有机银离子化合物可以更有效的发挥其作用。The water-based gel in the present invention is a viscous water-based gel containing a water-soluble organic silver ion compound. Its use method is very diverse. It can be similar to mouthwash, and an appropriate amount of the water-based gel of the present invention can be poured into the mouth. In the mouth, use the oral movement to evenly distribute the water-based gel to the damaged mucosa of the mouth, then hold the water-based gel in the mouth for a period of time, and then spit it out. Or it can be sprayed on the damaged oral mucosa in the mouth, or it can be sprayed deeper into the throat. It can also be smeared on damaged oral mucosa. Due to the viscous and shear-thinning characteristics of this aqueous gel, it can stay on the damaged oral mucosa for a long time, so that the water-soluble organic silver ion compound in the aqueous gel can play its role more effectively .
本发明的水性凝胶含有水溶性有机银离子化合物外还含有高分子增稠剂,其作用在于提高本发明的水性凝胶的黏度,适合的高分子增稠剂包含纤维素类(Cellulose)、压克力类(polyacrylate)、天然胶类、聚乙烯吡咯烷酮(polyvinylpyrrolidone)以及其他水性有机增稠剂,纤维素类增稠剂包含羧甲基纤维素纳(Sodium carboxylmethyl cellulose)、甲基纤维素(Methyl Cellulose)、羟丙基甲基纤维素(Hydroxypropylmethylcellulose)、羟丙基纤维素(Hydroxypropylcellulose)、羟乙基纤维素(Hydroxyethyl cellulose)、微晶纤维素(Microcrystalline cellulose)或其他水溶性具有增稠剂效能的纤维素衍生物,压克力类包含聚丙烯酸、聚丙烯酸钠、丙烯酸与其他压克力单体的共聚物、丙烯酸纳与其他压克力单体的共聚物或其他水溶性具有增稠剂效能的水溶性压克力聚合物,天然胶类包含包含瓜尔豆胶(Guar gum),琼脂(agar),黄原胶(Xanthan gum),海藻酸钠(sodium alginate),淀粉(starch),壳聚醣(chitosan),胶原蛋白(collagen),刺槐豆胶(Locust bean gum)或阿拉伯胶(gum Arabic)等,聚乙烯吡咯烷酮包含聚乙烯吡咯烷酮与乙烯吡咯烷酮和其他单体的共聚物。本发明的水性凝胶可以仅仅使用一种增稠剂,也可以两种以上的增稠剂合并使用。The aqueous gel of the present invention contains a water-soluble organic silver ion compound and also contains a polymer thickener, and its effect is to improve the viscosity of the aqueous gel of the present invention. A suitable polymer thickener includes Cellulose, Acrylic (polyacrylate), natural gum, polyvinylpyrrolidone (polyvinylpyrrolidone) and other water-based organic thickeners, cellulose thickeners include sodium carboxylmethyl cellulose, methyl cellulose ( Methyl Cellulose), Hydroxypropylmethylcellulose, Hydroxypropylcellulose, Hydroxyethyl cellulose, Microcrystalline cellulose or other water-soluble thickeners Efficient cellulose derivatives, acrylics include polyacrylic acid, sodium polyacrylate, copolymers of acrylic acid and other acrylic monomers, copolymers of sodium acrylate and other acrylic monomers, or other water-soluble thickeners Water-soluble acrylic polymer with agent performance, natural gum contains guar gum (Guar gum), agar (agar), xanthan gum (Xanthan gum), sodium alginate (sodium alginate), starch (starch) , chitosan (chitosan), collagen (collagen), locust bean gum (Locust bean gum) or gum Arabic (gum Arabic), etc., polyvinylpyrrolidone contains a copolymer of polyvinylpyrrolidone and vinylpyrrolidone and other monomers. The aqueous gel of the present invention may use only one kind of thickener, or two or more kinds of thickeners may be used in combination.
以上的高分子增稠剂除了提高本发明的水性凝胶的黏度外,还会赋予本发明的水性凝胶剪切稀化(Shear thinning)的特性,这种特性使得本发明的水性凝胶在使用的过程中可以较长时间的停留在口腔黏膜,让水性凝胶中的水溶性有机银离子化合物可以更有效的发挥其作用。In addition to improving the viscosity of the water-based gel of the present invention, the above polymer thickener will also give the water-based gel of the present invention the characteristics of shear thinning (Shear thinning), which makes the water-based gel of the present invention During use, it can stay in the oral mucosa for a long time, so that the water-soluble organic silver ion compound in the water-based gel can play its role more effectively.
剪切稀化的性质是一种非牛顿流体的特性,也就是流体的黏度随着剪切力的增加而降低的特性,与牛顿牛体的黏度不随减切力的改变而有所改变不同,有两种流体具有这种特性,一是拟塑态流体(Pseudoplastic fluid),另一是摇变减 黏流体(Thixotropic fluid),差异在于拟塑态流体的黏度改变不随时间变化而有所不同,摇变减黏流体的黏度除了随剪切力增加而降低,在剪切力降低回复的过程中黏度变化与剪切力增加时不同,也就是有时间的因素在其中,本发明的水性凝胶可以是拟塑态流体也可以是摇变减黏流体,因为二者皆具有剪切稀化的性质。The property of shear thinning is a characteristic of a non-Newtonian fluid, that is, the viscosity of the fluid decreases with the increase of the shear force, which is different from the viscosity of the Newtonian body that does not change with the change of the shear force. There are two kinds of fluids with this characteristic, one is pseudoplastic fluid (Pseudoplastic fluid), the other is thixotropic fluid (Thixotropic fluid), the difference is that the viscosity of pseudoplastic fluid does not vary with time, The viscosity of the thixotropic viscosity-breaking fluid decreases with the increase of the shear force, and the viscosity change is different from that of the increase of the shear force during the recovery process of the decrease of the shear force, that is, there is a time factor in it, and the aqueous gel of the present invention It can be a pseudoplastic fluid or a thixotropic viscous fluid, because both have the property of shear thinning.
剪切稀化的性质在本发明的水性凝胶使用时的具体优势显现在于让施用方法更容易为使用者接受,以及让水溶性有机银高分子能更长时间的接触受损的口腔黏膜以充分发挥其效用,The specific advantage of the property of shear thinning in the use of the hydrogel of the present invention is to make the application method more acceptable to the user, and to allow the water-soluble organic silver polymer to contact the damaged oral mucosa for a longer period of time. to fully utilize its effectiveness,
当水性凝胶以漱口液的形式使用时,被倒入口中时,口腔的运动对水性凝胶施以一剪切的力量,口腔运动的频率越快,此剪切力也就越大,由于本发明的水性凝胶具有剪切稀化的性质,所以其黏度会降低许多,低黏度的漱口液比高黏度的漱口液会让使用者更能接受,也会使得水性凝胶更容易且更完全的覆盖到口腔内每一处黏膜,不论是受损或未受损的黏膜都得以得到覆盖,当口腔运动结束,口中的水性凝胶被吐出后,由于口腔不再运动,也就是剪切力为零,残留在口腔黏膜上本发明的水性凝胶黏度增加而不易流动,因而得以停留在受损黏膜,而且因为黏度较高而不易为口腔中的唾液冲掉,使得水性凝胶得以较长时间的停留在受损伤的黏膜上,而水性凝胶中的水溶性有机银离子化合物也得以更有效的发挥其作用。When the water-based gel is used in the form of mouthwash, when it is poured into the mouth, the movement of the oral cavity exerts a shear force on the water-based gel. The faster the frequency of oral movement, the greater the shear force, because The water-based gel of the present invention has the property of shear thinning, so its viscosity will be much lower. A low-viscosity mouthwash will be more acceptable to users than a high-viscosity mouthwash, and it will also make the water-based gel easier to process. And more completely cover every mucous membrane in the oral cavity, whether it is damaged or undamaged mucous membranes can be covered. The shear force is zero, and the water-based gel of the present invention has increased viscosity and is not easy to flow when remaining on the oral mucosa, so it can stay on the damaged mucosa, and because of its high viscosity, it is not easy to be washed away by saliva in the oral cavity, making the water-based gel It can stay on the damaged mucosa for a long time, and the water-soluble organic silver ion compound in the water-based gel can also play its role more effectively.
当以喷剂的形式使用时,同样的在喷出的时候本发明的水性凝胶受到了喷出时喷瓶所施予的力量,以高速喷出,此时水性凝胶因剪切稀化特性而黏度降低,使得水性凝胶得以顺利喷出,当喷到受损口腔黏膜上时,此时水性凝胶由于喷头的作用力已经消失,黏度增加,因而得以较长时间的停留在受损黏膜上,水性凝胶中的水溶性有机银离子化合物也得以更有效的发挥其作用。When used in the form of a spray, the same water-based gel of the present invention is subjected to the power given by the spray bottle when spraying out, and is sprayed at a high speed. At this time, the water-based gel is thinned by shearing characteristics and the viscosity is reduced, so that the water-based gel can be sprayed out smoothly. When it is sprayed on the damaged oral mucosa, the force of the nozzle has disappeared and the viscosity of the water-based gel has increased, so it can stay on the damaged oral mucosa for a long time. On the mucous membrane, the water-soluble organic silver ion compound in the aqueous gel can also play its role more effectively.
当以涂抹的方式使用时,同样的在涂抹的时候本发明的水性凝胶受到了涂抹时所施予的力量而黏度降低,使得水性凝胶得以顺利的被涂抹到受损口腔黏膜上时,当涂抹动作停止时,此时由于涂抹的作用力已经消失,本发明的水性凝胶黏度增加,因而得以较长时间的停留在受损黏膜上,水性凝胶中的水溶性有机银离子化合物也得以更有效的发挥其作用。When used in the way of smearing, the same water-based gel of the present invention is subjected to the force applied when smearing and the viscosity is reduced, so that the water-based gel can be smoothly applied to the damaged oral mucosa. When the smearing action stops, the viscosity of the water-based gel of the present invention increases because the force of smearing has disappeared, so it can stay on the damaged mucosa for a long time, and the water-soluble organic silver ion compound in the water-based gel also to play its role more effectively.
剪切稀化的性质通常是以摇变指数(Thixotropic Index)来表示,摇变指数是指在低与高两种剪切力所量得的黏度比,摇变指数若等于1,就代表这个流体是牛顿流体,若摇变指数大于1则代表这个流体是非牛顿流体而且具有剪切稀化的性质。The nature of shear thinning is usually represented by Thixotropic Index, which refers to the viscosity ratio measured under low and high shear forces. If the Thixotropic Index is equal to 1, it represents the The fluid is a Newtonian fluid, and if the thixotropy index is greater than 1, it means that the fluid is non-Newtonian and has the property of shear thinning.
流体的量测有许多的方法,比较便利的两种方法是Cone and Plate以及Spindle,代表性的仪器厂商是德州仪器公司(Texas Instrument)与AMETEK Brookfield公司,这两种仪器是藉由Cone与spindle的转动来量测流体的黏度,剪切力的大小就以cone与spindle的转速来代表。本发明所定义的摇变指数(Thixotropic Index)是指在cone或spindle的转速是每秒1转与每秒10转时所量得的黏度比。There are many methods for fluid measurement. The two most convenient methods are Cone and Plate and Spindle. Representative instrument manufacturers are Texas Instruments and AMETEK Brookfield. These two instruments are based on Cone and Spindle. The rotation of the fluid is used to measure the viscosity of the fluid, and the magnitude of the shear force is represented by the rotational speed of the cone and the spindle. The thixotropic index defined in the present invention refers to the viscosity ratio measured when the rotating speed of the cone or spindle is 1 revolution per second and 10 revolutions per second.
本发明水性凝胶的摇变指数必须大于1.1,更佳的是大于1.5,再更佳的是大于2。The thixotropy index of the aqueous gel of the present invention must be greater than 1.1, more preferably greater than 1.5, and more preferably greater than 2.
本发明中水性凝胶内所含有对治疗口腔黏膜炎有效的物质是水溶性有机银离子化合物,此水溶性有机银离子化合物可以是小分子的有机银离子化合物或者是大分子的有机银离子化合物。In the present invention, the effective substance contained in the aqueous gel for treating oral mucositis is a water-soluble organic silver ion compound, and the water-soluble organic silver ion compound can be a small molecule organic silver ion compound or a macromolecular organic silver ion compound .
本发明的小分子有机银离子化合物是指分子量小于1000的有机银盐,包含但不限于有机羧酸银盐、有机璜酸银盐与有机杂环化合物与银离子的错合物,这些有机银离子化合物常温时(25℃)在水中的溶解度必须大于0.01%,最好是大 于0.1%,更佳的是大于1%。The small-molecule organic silver ion compound of the present invention refers to organic silver salts with a molecular weight less than 1000, including but not limited to organic silver salts of carboxylates, organic silver sulfonates, and complexes of organic heterocyclic compounds and silver ions. The solubility of the ionic compound in water at normal temperature (25°C) must be greater than 0.01%, preferably greater than 0.1%, more preferably greater than 1%.
本发明有机羧酸银盐可以是一般含碳数为1至10的烷基有机羧酸银盐,例如甲酸银、乙酸银、丙酸银、丁酸银等,或者是含有其他水溶性官能基的烷基有机羧酸银盐,例如在欧洲专利EP2159270A1中所提到化学通式为CH 3-O-(CH 2CH 2O) n-CH-COOAg的有机羧酸银盐,或者是其他结构的有机羧酸银盐。 The organic silver carboxylate salt of the present invention can be the alkyl organic carboxylate silver salt that generally contains 1 to 10 carbon number, such as silver formate, silver acetate, silver propionate, silver butyrate etc., or it may contain other water-soluble functional groups Alkyl organic carboxylic acid silver salts, such as the organic carboxylic acid silver salts with the chemical formula CH 3 -O-(CH 2 CH 2 O) n -CH-COOAg mentioned in European Patent EP2159270A1, or other structures silver salts of organic carboxylic acids.
本发明的有机璜酸银盐可以是甲苯磺酸银或其他有机磺酸银盐。The organic sulfonate silver salt of the present invention can be silver toluenesulfonate or other organic sulfonate silver salts.
本发明的有机杂环化合物与银离子的错合物可以是咪唑化合物(imidazole compound)或三唑化合物(triazole compound)与银的错合物,例如在文献(Dalton Trans.,2009,6985-6990)中所研究的水溶性咪唑/银错合物与水溶性三唑/银错合物,或者其他杂环化合物与银的错合物。The complex compound of organic heterocyclic compound and silver ion of the present invention can be the complex compound of imidazole compound (imidazole compound) or triazole compound (triazole compound) and silver, for example in document (Dalton Trans.,2009,6985-6990 ) The water-soluble imidazole/silver complexes and water-soluble triazole/silver complexes studied in ), or the complexes of other heterocyclic compounds and silver.
本发明的大分子有机银离子化合物可以是美国专利US9918478B2中所揭露的水溶性压克力高分子银盐,也可以是其他分子量大于1000以上的含有银离子的水溶性高分子。The macromolecular organic silver ion compound of the present invention can be the water-soluble acrylic polymer silver salt disclosed in US Pat.
本发明的水性凝胶中银的含量必须至少大于10ppm,最好是大于50ppm,更佳的是大于150ppm,银离子含量愈高,对于治疗口腔黏膜炎的效果也愈佳。The silver content in the aqueous gel of the present invention must be at least greater than 10ppm, preferably greater than 50ppm, and more preferably greater than 150ppm. The higher the silver ion content, the better the effect of treating oral mucositis.
本发明的水性凝胶中除了以上的成分外,还可以加入适当的调味剂以增加使用者的接受度,例如甜味剂或凉味剂。In addition to the above ingredients, the aqueous gel of the present invention can also add appropriate flavoring agents to increase user acceptance, such as sweeteners or cooling agents.
具体实施方式Detailed ways
水性凝胶的配制:Preparation of water-based gel:
水性凝胶的原料包含用作增稠剂的聚乙烯吡咯烷酮(Polyvinylpyrrolidone,
Figure PCTCN2021120097-appb-000001
BASF)以及羟丙基甲基纤维素(Hydroxypropylmethylcellulose,Metolose 90SH-100000SR, Shin-Etsu),所使用的水溶性有机银离子化合物是大分子的丙烯酸钠-丙烯酸银共聚物(Poly(sodium acrylate-co-silver acrylate),由存升泰国际有限公司所提供,其所提供的是丙烯酸钠-丙烯酸银共聚物水溶液(Poly(sodium acrylate-co-silver acrylate)solution),丙烯酸钠-丙烯酸银共聚物水溶液中的丙烯酸钠-丙烯酸银共聚物含量是2.5%,银离子含量是1%,也就是每一丙烯酸钠-丙烯酸银共聚物分子中含有平均约40%的银,而丙烯酸钠-丙烯酸银共聚物的分子量大于5,000,000。
The raw material of the aqueous gel contains polyvinylpyrrolidone (Polyvinylpyrrolidone,
Figure PCTCN2021120097-appb-000001
BASF) and hydroxypropylmethylcellulose (Hydroxypropylmethylcellulose, Metolose 90SH-100000SR, Shin-Etsu), the water-soluble organic silver ion compound used is macromolecular sodium acrylate-silver acrylate copolymer (Poly(sodium acrylate-co -silver acrylate), provided by Cunshengtai International Co., Ltd., which provides sodium acrylate-silver acrylate copolymer solution (Poly(sodium acrylate-co-silver acrylate) solution), sodium acrylate-silver acrylate copolymer solution The sodium acrylate-silver acrylate copolymer content is 2.5%, and the silver ion content is 1%, that is, each sodium acrylate-silver acrylate copolymer molecule contains an average of about 40% silver, while The molecular weight is greater than 5,000,000.
水性凝胶的组成如下表所示,如表所示,所配得水性凝胶中的含银量是150ppm(0.015%),以Brookfield DV1流变仪测得在每秒1转时的黏度是367cps,而在每秒10转时的黏度是298cps,此水性凝胶的摇变指数是1.23。The composition of the aqueous gel is shown in the table below, as shown in the table, the silver content in the prepared aqueous gel is 150ppm (0.015%), and the viscosity measured at 1 revolution per second with the Brookfield DV1 rheometer is 367cps, and the viscosity at 10 revolutions per second is 298cps, the thixotropic index of this aqueous gel is 1.23.
Figure PCTCN2021120097-appb-000002
Figure PCTCN2021120097-appb-000002
案例1:Case 1:
男病患,59岁,罹患下咽癌,接受同步化学放射治疗(CCRT,concurrent chemoradiotherapy),在其治疗开始后的第23天(T0)开始给予水性凝胶的介入,请其每日饭后以及睡前漱口使用,每次含漱至少一分钟以上,漱完后将水性凝胶吐出即可,每周按口腔评估指南(OAG,Oral Assesment Guildline)由口腔外科医师进行口 腔的检查,共进行4周(T1至T4)如此直到其疗程结束,结果如下表所示:A 59-year-old male patient, suffering from hypopharyngeal cancer, received concurrent chemoradiotherapy (CCRT, concurrent chemoradiotherapy). The intervention of hydrogel was given on the 23rd day (T0) after the start of the treatment, and he was asked to take it after meals every day. As well as gargling before going to bed, gargle for at least one minute each time, spit out the water-based gel after rinsing, and have a weekly oral examination by an oral surgeon according to the Oral Assessment Guildline (OAG, Oral Assessment Guildline). Carry out 4 weeks (T1 to T4) so until the end of its course of treatment, the results are shown in the table below:
Figure PCTCN2021120097-appb-000003
Figure PCTCN2021120097-appb-000003
由表中的结果可以看出,在T0时病患额状况非常差,在介入的额第1周(T1),其状况即改善非常多,在介入的第2周(T2)以后其状况便趋于稳定。It can be seen from the results in the table that the patient's condition was very poor at T0, and his condition improved a lot in the first week of intervention (T1), and his condition improved after the second week of intervention (T2). becoming steady.
案例2:Case 2:
男病患,51岁,罹患咽喉癌,接受同步化学放射治疗(CCRT,concurrent chemoradiotherapy),在其治疗开始后的第16天(T0)开始给予水性凝胶的介入,请其每日饭后以及睡前漱口使用,每次含漱至少一分钟以上,漱完后将水性凝胶吐出即可,每周按口腔评估指南(OAG,Oral Assesment Guildline)由口腔外科医师进行口腔的检查,共进行4周(T1至T4)如此直到其疗程结束,结果如下表所示:A 51-year-old male patient, suffering from throat cancer, received concurrent chemoradiotherapy (CCRT, concurrent chemoradiotherapy). The intervention of hydrogel was given on the 16th day (T0) after the start of the treatment, and he was asked to eat after meals and Rinse your mouth before going to bed, gargle for at least one minute each time, spit out the water-based gel after rinsing, and have a weekly oral examination by an oral surgeon according to the Oral Assessment Guildline (OAG, Oral Assessment Guildline). 4 weeks (T1 to T4) until the end of the course of treatment, the results are shown in the table below:
Figure PCTCN2021120097-appb-000004
Figure PCTCN2021120097-appb-000004
由表中的结果可以看出,在T0时病患的状况非常差,在介入的第1周(T1),其状况即改善非常多,在介的第2周(T2)以后其状况便趋于稳定。From the results in the table, it can be seen that the condition of the patient was very poor at T0, and in the first week of intervention (T1), his condition improved a lot, and after the second week of intervention (T2), his condition became more and more stable. more stable.
案例3:Case 3:
女病患,40岁,罹患口咽癌,接受放射治疗,在其治疗开始后的第27天(T0)开始给予水性凝胶的介入,请其每日饭后以及睡前漱口使用,每次含漱至少一分钟以上,漱完后将水性凝胶吐出即可,每周按口腔评估指南(OAG,Oral Assesment Guildline)由口腔外科医师进行口腔的检查,共进行4周(T1至T4)如此直到其疗程结束,结果如下表所示:A 40-year-old female patient, suffering from oropharyngeal cancer, received radiation therapy. The intervention of hydrogel was given on the 27th day (T0) after the start of treatment. She was asked to rinse her mouth after meals and before going to bed every day. Gargle for at least one minute at a time, and spit out the water-based gel after rinsing. The oral cavity is checked by an oral surgeon according to the Oral Assessment Guildline (OAG, Oral Assessment Guildline) every week for a total of 4 weeks (T1 to T4) So until the end of its course of treatment, the results are shown in the table below:
Figure PCTCN2021120097-appb-000005
Figure PCTCN2021120097-appb-000005
由表中的结果可以看出,在T0时病患的状况尚未发展至非常糟的状况,在介入的第1周及第2周(T1&T2),其状况并未恶化甚至有些改善,在介入的第3周(T3)以后其状况已有改善进步直到疗程结束(T4)。From the results in the table, it can be seen that the condition of the patient has not developed to a very bad condition at T0, and in the first and second weeks of intervention (T1&T2), the condition has not deteriorated or even improved somewhat. After the third week (T3), the condition has improved and progressed until the end of the course of treatment (T4).

Claims (14)

  1. 一种治疗口腔黏膜炎的方法,其特征在于,包含提供一含有水溶性有机银离子化合物的水性凝胶,以及以适当的施用方法将此水性凝胶施用于受损的口腔黏膜,其中水性凝胶的银含量大于10ppm。A method for treating oral mucositis, characterized in that it includes providing a water-based gel containing a water-soluble organic silver ion compound, and applying the water-based gel to damaged oral mucosa with an appropriate application method, wherein the water-based gel The silver content of the glue is greater than 10 ppm.
  2. 根据权利要求1所述的治疗口腔黏膜炎的方法,其中,水溶性有机银离子化合物是分子量小于1000的小分子量有机银离子化合物或分子量大于1000的大分子量有机银离子化合物。The method for treating oral mucositis according to claim 1, wherein the water-soluble organic silver ion compound is a small molecular weight organic silver ion compound with a molecular weight less than 1000 or a large molecular weight organic silver ion compound with a molecular weight greater than 1000.
  3. 根据权利要求2所述的治疗口腔黏膜炎的方法,其中,小分子量有机银离子化合物是有机羧酸银盐、有机璜酸银盐或有机杂环化合物与银离子的错合物。The method for treating oral mucositis according to claim 2, wherein the low-molecular-weight organic silver ion compound is an organic silver carboxylate, an organic silver sulfonate, or a complex compound of an organic heterocyclic compound and silver ions.
  4. 根据权利要求2所述的治疗口腔黏膜炎的方法,其中,大分子量有机银离子化合物是水溶性压克力高分子银盐。The method for treating oral mucositis according to claim 2, wherein the large molecular weight organic silver ion compound is a water-soluble acrylic polymer silver salt.
  5. 根据权利要求1所述的治疗口腔黏膜炎的方法,其中,适当的施用方法是漱口、喷剂或涂抹。The method for treating oral mucositis according to claim 1, wherein the appropriate application method is mouthwash, spray or smear.
  6. 根据权利要求1所述的治疗口腔黏膜炎的方法,其中,受损的口腔黏膜是世界卫生组织口腔黏膜炎分级标准中5个等级黏膜中的任一黏膜。The method for treating oral mucositis according to claim 1, wherein the damaged oral mucosa is any one of the five levels of mucosa in the World Health Organization's oral mucositis grading standard.
  7. 根据权利要求1所述的治疗口腔黏膜炎的方法,其中,水性凝胶的触变指数大于1.1。The method for treating oral mucositis according to claim 1, wherein the thixotropic index of the aqueous gel is greater than 1.1.
  8. 一种用于治疗口腔黏膜炎的水性凝胶,其特征在于,其成分中含有水溶性有机银离子化合物以及高分子增稠剂,此水性凝胶的银含量大于10ppm。A water-based gel for treating oral mucositis is characterized in that its components contain a water-soluble organic silver ion compound and a polymer thickener, and the silver content of the water-based gel is greater than 10 ppm.
  9. 根据权利要求8所述的水性凝胶,其中,水溶性有机银离子化合物在水中的溶解度大于0.01%。The aqueous gel according to claim 8, wherein the solubility of the water-soluble organic silver ion compound in water is greater than 0.01%.
  10. 根据权利要求8所述的水性凝胶,其中,水溶性有机银离子化合物是分子量小于1000的小分子量有机银离子化合物或分子量大于1000的大分子量有机银离子化合物。The aqueous gel according to claim 8, wherein the water-soluble organic silver ion compound is a small molecular weight organic silver ion compound with a molecular weight of less than 1000 or a large molecular weight organic silver ion compound with a molecular weight greater than 1000.
  11. 根据权利要求10所述的水性凝胶,其中,小分子量有机银离子化合物是有机羧酸银盐、有机璜酸银盐或有机杂环化合物与银离子的错合物。The aqueous gel according to claim 10, wherein the low molecular weight organic silver ion compound is an organic silver carboxylate, an organic silver sulfonate or a complex compound of an organic heterocyclic compound and silver ions.
  12. 根据权利要求10所述的水性凝胶,其中,大分子量有机银离子化合物是水溶性压克力高分子银盐。The aqueous gel according to claim 10, wherein the large molecular weight organic silver ion compound is a water-soluble acrylic polymer silver salt.
  13. 根据权利要求8所述的水性凝胶,其中,高分子增稠剂是纤维素类、压克力类、天然胶类、聚乙烯吡咯烷酮或聚氧乙烯,可以是单一或两种以上合并使用。The aqueous gel according to claim 8, wherein the macromolecule thickener is cellulose, acrylic, natural gum, polyvinylpyrrolidone or polyoxyethylene, and can be used singly or in combination of two or more.
  14. 根据权利要求8所述的水性凝胶,其中,其触变指数大于1.1。The aqueous gel according to claim 8, wherein its thixotropic index is greater than 1.1.
PCT/CN2021/120097 2021-09-24 2021-09-24 Method and aqueous gel for treating oral mucositis WO2023044700A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/CN2021/120097 WO2023044700A1 (en) 2021-09-24 2021-09-24 Method and aqueous gel for treating oral mucositis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2021/120097 WO2023044700A1 (en) 2021-09-24 2021-09-24 Method and aqueous gel for treating oral mucositis

Publications (1)

Publication Number Publication Date
WO2023044700A1 true WO2023044700A1 (en) 2023-03-30

Family

ID=85719146

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2021/120097 WO2023044700A1 (en) 2021-09-24 2021-09-24 Method and aqueous gel for treating oral mucositis

Country Status (1)

Country Link
WO (1) WO2023044700A1 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105209049A (en) * 2013-05-02 2015-12-30 医学科技研究公司 Antimicrobial compositions and methods of making the same
US20160243164A1 (en) * 2011-05-05 2016-08-25 Celacare Technologies, Llc Antimicrobial silver hydrogel composition for the treatment of burns and wounds
TWI566783B (en) * 2015-08-21 2017-01-21 王式禹 Mouthwash comprising silver polyacrylate
CN106397640A (en) * 2015-04-21 2017-02-15 王式禹 water-soluble antibacterial acrylic polymer silver salt
US20190388392A1 (en) * 2018-06-11 2019-12-26 Abon Pharmaceuticals Llc. Oral eliglustat transmucosal delivery system

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160243164A1 (en) * 2011-05-05 2016-08-25 Celacare Technologies, Llc Antimicrobial silver hydrogel composition for the treatment of burns and wounds
CN105209049A (en) * 2013-05-02 2015-12-30 医学科技研究公司 Antimicrobial compositions and methods of making the same
CN106397640A (en) * 2015-04-21 2017-02-15 王式禹 water-soluble antibacterial acrylic polymer silver salt
TWI566783B (en) * 2015-08-21 2017-01-21 王式禹 Mouthwash comprising silver polyacrylate
US20190388392A1 (en) * 2018-06-11 2019-12-26 Abon Pharmaceuticals Llc. Oral eliglustat transmucosal delivery system

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TANG, YUXIN: "Analysis of the Effect of Active Silver Ion Antibacterial Liquid Nursing on Oral Ulcers Caused by Chemotherapy", ELECTRONIC JOURNAL OF GENERAL STOMATOLOGY, vol. 6, no. 12, 1 April 2019 (2019-04-01), pages 77 - 77, XP093053583, DOI: 10.16269/j.cnki.cn11-9337/r.2019.12.057 *

Similar Documents

Publication Publication Date Title
JP2927850B2 (en) Topical preparations for the treatment of symptoms of teeth and their supporting tissues
TWI478728B (en) Aqueous oral care compositions
JP5847833B2 (en) Topical composition for preserving or restoring the intact state of the mucosa
DK166562B1 (en) ORAL AND DENTAL CARE
AU2011278235B2 (en) Composition for the treatment of superficial lesions
JPS62123133A (en) Preparation of dry carrier for controlled long life blended medicine and dry carrier thereby
EP3056195A1 (en) Compositions comprising hyaluronic acid and beta-glucan for topical applications in oral cavity
WO2022142383A1 (en) Oral product containing hyaluronic acid, and preparation method therefor
JP2010138080A (en) Oral composition
WO2018076856A1 (en) Eugenol oral ulcer membrane and preparation method therefor
TWI532504B (en) Paraben-free preservative systems for oral care compositions
RU2358748C2 (en) Local compositions restoring nail structure
JP4828025B2 (en) Stannous fluoride composition for the treatment of dental hypersensitivity
CN101455654B (en) Arginine ibuprofen gel and preparation method thereof
RU2420257C1 (en) Dental gel with chlorhexidine and dibunole for treatment of inflammatory diseases of parodentium and oral cavity mucosa
WO2023044700A1 (en) Method and aqueous gel for treating oral mucositis
TW202214267A (en) Method for treating oral mucositis and aqueous gel for the same
BR112020006262B1 (en) AQUEOUS COMPOSITION FOR ORAL TREATMENT WITH FLUORIDE AND ITS USE
US20240100042A1 (en) Brucine gel plaster and preparation method and use thereof
CN108030792A (en) A kind of preparation process of the liquid anti-inflammatory sterilized composition of the propolis containing honey
CN106620673A (en) Hydrogel for treating infant dental ulcer and preparation method of hydrogel
CN106074305A (en) A kind of Noni fruit toothpaste with oral mucosa protective effect and preparation method thereof
JP3503880B2 (en) Oral composition
BR112021008102A2 (en) oral mucosa carrier and protector
ES2898839T3 (en) Aqueous formulation for the topical treatment of skin diseases

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21957836

Country of ref document: EP

Kind code of ref document: A1